On June 12, 2024 Immorta Bio Inc, a science-based Life Extension company reported positive preclinical findings utilizing its senescent cell-killing immunotherapeutic product SenoVax in a model of non-small cell lung cancer (Press release, Immorta Bio, JUN 12, 2024, View Source [SID1234644294]). The results, which are reported in a filed patent, demonstrate successful induction of immunity to senescent cells surrounding lung cancer cells, and reproducible regression of established tumors. The SenoVax immunotherapy was administered in absence of other cancer killing therapeutics.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"It has been published that tumors surround themselves with senescent cells, with negative correlations between the amount of senescent cells and patient survival1. Furthermore, increased resistance to cancer therapies such as chemotherapy2, radiation therapy3, and immunotherapy4 is associated with accumulation of senescent cells," said Dr. Thomas Ichim, President and CSO of Immorta Bio. "The fact that we are able to induce regression of tumors by simply killing the senescent cells that surround them, without other interventions, points to the potency of our approach."
The Company is currently in the late phase of preclinical development and plans to file an Investigational New Drug (IND) application with the FDA shortly to initiate treatment of advanced lung cancer patients.
"Immorta Bio is a Scientific Longevity Company. In that regard we are developing two longevity therapeutics platforms: Cellular Rejuvenation and Senolytic Immunotherapy (SenoVax)," said Dr. Boris Reznik, Chairman and CEO of Immorta Bio. "The results disclosed today are part of our second technology platform, which augments the immune system’s natural tendency to ‘clean up’ dysfunctional and senescent cells. Application of SenoVax to cancer treatment not only can potentially produce some effective oncology drug, but also is proving its potency in Senolytic life extension applications."